Alnylam Pharmaceuticals: RBC cuts target price to $280 from $345
ALNY•RBC cut its target price for Alnylam Pharmaceuticals to $280 from $345.
Related News
Daiichi Sankyo, AstraZeneca team with Summit Therapeutics on cancer drug trials
SMMT•
TD Cowen cuts Saia target price to $393 from $400
SAIA•
Merit Medical Systems target price raised by Canaccord Genuity to $121 from $94
MMSI•
Brunswick raises target price to $67 from $66
BC•
Centerra Gold Inc.: CIBC raises target price to C$41.00 from C$40.00
CGAU•